Table 6.

Age-, sex- and body fat %-adjusted linear mixed regression estimates (standardized β coefficients (95% CI)) between MRS-measured LFC, body composition and cardiometabolic risk factors.

	LFC MRSa (%)
	Model 1		Model 2
	β	p	β	p
Body fat, %	0.50 (0.10, 0.89)	0.02
Waist, cm	0.58 (0.31, 0.85)	0.0001	0.55 (0.20, 0.91)	0.003
BMI, kg/m2	0.34 (0.05, 0.64)	0.03	0.17 (− 0.23, 0.57)	0.40
SBP, mmHg	− 0.08 (− 0.41, 0.26)	0.64	− 0.11 (− 0.42, 0.20)	0.49
DBP, mmHg	0.13 (− 0.18, 0.45)	0.40	0.08 (− 0.23, 0.38)	0.61
Resting heart rate, bpm	− 0.21 (− 0.52, 0.11)	0.19	− 0.19 (− 0.47, 0.09)	0.18
BP medication	0.08 (− 0.26, 0.42)	0.65	0.02 (− 0.31, 0.34)	0.90
Cholesterol medication	− 0.06 (− 0.38, 0.26)	0.70	0.02 (− 0.29, 0.32)	0.91
f-Glucose, mmol/l	− 0.11 (− 0.44, 0.21)	0.49	− 0.13 (− 0.43, 0.17)	0.40
f-Insulin, mU/l	0.41 (0.09, 0.72)	0.01	0.31 (− 0.02, 0.63)	0.06
HOMA-IR	0.38 (0.06, 0.70)	0.02	0.28 (− 0.004, 0.60)	0.084
M-value, mg/kg/min	− 0.43 (− 0.72, − 0.14)	0.005	− 0.34 (− 0.67, − 0.01)	0.047
HbA1c, mmol/mol	0.54 (0.27, 0.81)	0.0003	0.48 (0.20, 0.75)	0.001
Triglycerides, mmol/l	0.38 (0.09, 0.67)	0.01	0.38 (0.11, 0.64)	0.006
Cholesterol, mmol/l	0.22 (− 0.10, 0.53)	0.18	0.22 (− 0.07, 0.52)	0.14
HDL, mmol/l	− 0.18 (− 0.57, 0.17)	0.29	− 0.18 (− 0.52, 0.17)	0.31
LDL, mmol/l	0.18 (− 0.13, 0.49)	0.25	0.18 (− 0.12, 0.47)	0.23
ALT, U/l	0.50 (0.23, 0.78)	0.0007	0.46 (0.20, 0.73)	0.001
AST, U/l	0.24 (− 0.10, 0.59)	0.16	0.32 (− 0.003, 0.64)	0.052
GGT, U/l	0.30 (− 0.01, 0.60)	0.054	0.29 (0.01, 0.57)	0.04

Model 1 adjusted for age and sex.

Model 2 adjusted for age, sex and body fat %

ALT alanine aminotransferase, AST aspartate aminotransferase, BP blood pressure, DBP diastolic blood pressure, f fasting, GGT γ-glutamyltransferase, HbA_1c hemoglobin A_1c, HOMA-IR homeostatic model assessment for insulin resistance, LFC liver fat content, MRS magnetic resonance spectroscopy, M-value whole-body insulin sensitivity, SBP systolic blood pressure.

^alog10 transformed variables.

Significant values are in bold.